Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.8K
1.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

66
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer risk with methotrexate-TNF antagonist combination therapy compared to TNF-antagonist monotherapy in IBD.

Inflammatory bowel diseases·2026
Same author

Toward Artificial Intelligence-driven Clinical Decision Support Tools in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same author

Statistics and AI - A Fireside Conversation.

Harvard data science review·2026
Same author

Predicting the timing of first sustained cognitive worsening in Alzheimer's disease using real-world clinical data and machine learning.

medRxiv : the preprint server for health sciences·2026
Same author

Nonparametric estimation of the total treatment effect with multiple outcomes in the presence of terminal events.

Biometrics·2026
Same author

Stratification of Alzheimer's disease patients using knowledge-guided unsupervised latent factor clustering with electronic health record data.

Communications medicine·2026

Related Experiment Video

Updated: Mar 23, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K

Identifying predictive markers for personalized treatment selection.

Yuanyuan Shen1, Tianxi Cai1

  • 1Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, U.S.A.

Biometrics
|March 22, 2016
PubMed
Summary

This study introduces a new kernel machine (KM) score test to identify predictive biomarkers for personalized treatment selection. The KM score test outperforms the standard Wald test, especially with complex marker effects and correlated predictors.

Keywords:
Kernel PCAKernel machinePerturbationScore testTreatment selection

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.7K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 23, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.9K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.7K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Area of Science:

  • Biostatistics
  • Genomics
  • Personalized Medicine

Background:

  • Treatment effectiveness and risks vary significantly across patient subgroups.
  • Individualized treatment selection using patient information is gaining prominence.
  • Genetic and molecular markers are crucial for guiding treatment decisions in diseases like HIV and breast cancer.

Purpose of the Study:

  • To develop an efficient method for selecting predictive biomarkers for individualized treatment rules (ITRs).
  • To address limitations of the standard Wald test in identifying markers with nonlinear effects or high correlation.

Main Methods:

  • Proposed a kernel machine (KM) score test for identifying markers predictive of treatment differences.
  • Evaluated the KM score test's performance through simulation studies.
  • Applied the method to analyze data from two randomized clinical trials.

Main Results:

  • The KM-based score test demonstrated higher power than the Wald test for nonlinear marker effects and binary outcomes.
  • The proposed method showed superior performance compared to the Wald test with high-dimensional and correlated predictors.
  • The KM score test effectively identified predictive biomarkers in real-world clinical trial data.

Conclusions:

  • The kernel machine score test offers a powerful and efficient approach for biomarker selection in personalized treatment strategies.
  • This method enhances the identification of markers that predict individualized treatment effects, moving beyond traditional approaches.
  • The findings support the use of KM score tests in clinical research for optimizing treatment selection.